Abstract 1768
Background
Taste changes can frequently be observed in oncological patients undergoing chemotherapy and are reported as being among the most distressing side effects, along with fatigue, nausea, vomiting, and hair loss. The prevalence of taste changes have been reported in the range of 46%–77%. The aim of this descriptive study was to evaluate taste changes experienced by cancer patients who receive chemotherapy and associated factors with taste changes.
Methods
This is a descriptive a study. The sample of the study consisted of 154 patients who received chemotherapy at Gayrettepe Florence Nightingale Hospital during the period of February 2018 to July 2018. Data were collected by using the patient İnformation form and Chemotherapy-induced Taste Alteration Scale (CiTAS). Mann-Whitney U test, Kruskal-Wallis test, and Spearman Correlation analysis were used to evaluate the data.
Results
The mean age of patients was 57,40±12,748 years, 62.3% of them were women, 43.5% of them were university graduates, 73.4% were married and 70.8% of them were employed in any job. According to CiTAS scores, the most discomfort in taste patients experienced was because of nausea, vomiting, odor disturbance and loss of appetite during the chemotherapy process. According to CiTAS score the least discomfort experienced by patients were tasting basic flavors including the taste of the sweet, salty, bitter flavors and the broth. As a result of the comparison of CiTAS score some sociodemographic and medical characteristics of patients, it was found that women experience more paraguzi and fantoguzi than men. As the age of the patients increased, the problems in taste were decreased. Patients who do not take other drugs than chemotherapy have fewer taste problems.
Conclusions
In conclusion, it is recommended to include changes in taste sensation along with other side effects in the evaluation of treatment-related processes of cancer patients, and to add practices related to management of taste changes in the care plan of the patients by taking into account the factors that may be associated with taste.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2438 - Professional Quality of Life, Perceived Stress and Psychological Resistance Levels of Oncology-Hematology Nurses and the Factors Affecting
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
3541 - Representation of cancer survivors’ preferences in policies for supportive care: Implications for oncology nursing
Presenter: Samantha Mayo
Session: Poster Display session 3
Resources:
Abstract
5093 - Vaginal moisturizing post PDR-Pulse Dose Rate Brachytherapy.
Presenter: Pilar Fernández
Session: Poster Display session 3
Resources:
Abstract
1066 - The stomized, chemo and radiotreated patient vs untreated patient: complications and comparison with data literature
Presenter: Cristoforo Ferrero
Session: Poster Display session 3
Resources:
Abstract
1724 - Evaluating the role of clinical nurse specialist
Presenter: Anita Zeneli
Session: Poster Display session 3
Resources:
Abstract
3753 - Role of the Advanced Practice Nurse (APN) in a Functional Unit for Lung cancer at the Catalan Institute of Oncology
Presenter: Isabel Brao
Session: Poster Display session 3
Resources:
Abstract
2676 - A bottom-up approach for prioritising the scientific activities of the Italian Association of Cancer Nurses (AIIAO): rationale and topic identification
Presenter: Valentina Biagioli
Session: Poster Display session 3
Resources:
Abstract
575 - Investigating quality of care for people with cancer and dementia
Presenter: Naomi Farrington
Session: Poster Display session 3
Resources:
Abstract
5578 - Two years of BRCA1 and BRCA2 somatic External Quality Assessment with Gen&tiss Tiss scheme in France
Presenter: Kelly Dufraing
Session: Poster Display session 3
Resources:
Abstract
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract